戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ns with cisatracurium vs. 35 to 85 mins with atracurium).
2  long-term, relatively high-dose infusion of atracurium.
3 tized patients displayed a negative BAT with atracurium.
4 .2 microg/kg/min, and for patients receiving atracurium 10.4 +/- 0.9 microg/kg/min.
5  Train-of-Four ratio (cisatracurium 60 mins, atracurium 57 mins), although there was considerable int
6 s a precursor in the production of the drugs atracurium and cisatracurium, and papaverine is used as
7 f the infusion, and plasma concentrations of atracurium and laudanosine were measured at, and after,
8 t patients with perioperative anaphylaxis to atracurium and seven individuals experiencing perioperat
9                                              Atracurium and vecuronium were the most commonly used ag
10                  Cisatracurium, an isomer of atracurium, appears to be a suitable agent for providing
11  or best clinical assessment while receiving atracurium by continuous infusion.
12                      However, metocurine and atracurium could potentiate the responses of fetal-type
13                                       Of the atracurium-exposed individuals with a negative atracuriu
14                         The patient received atracurium for 38 days, at rates ranging from 0.3 to 0.9
15 ndepolarizing neuromuscular blocking agents (atracurium, gallamine, metocurine, and pancuronium) to a
16                                       Use of atracurium in high doses or for a long period of time ha
17 The BAT proves to be a useful diagnostic for atracurium-induced anaphylaxis and may be complementary
18       Despite long-term use of high doses of atracurium infusion and the increased elimination half-l
19 asured at, and after, the termination of the atracurium infusion.
20                                   Allergy to atracurium is a rare condition with serious consequences
21                                              Atracurium is sometimes used for muscle relaxation in pa
22 +/- 4.2 [SEM] hrs), and 21 patients received atracurium (mean duration 46.1 +/- 5.8 hrs).
23 ity of the basophil activation test (BAT) in atracurium sensitization and to investigate its role in
24                   ROC analyses between eight atracurium-sensitized patients and seven nonexposed cont
25 racurium-exposed individuals with a negative atracurium skin test (ST), two individuals had a clear p
26          Although most patients demonstrated atracurium tolerance over time, there was no difference
27                     Basophil activation with atracurium was analysed flow cytometrically.
28                                          BAT atracurium was positive in one cisatracurium-sensitized
29  by continuous infusions of cisatracurium or atracurium were administered.
30            The interaction of metocurine and atracurium with acetylcholine at fetal-type receptors co